stockrowImmunityBio, Inc.
IBRX Healthcare Biotechnology
ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024.
- Revenue
- +93.9%
- EPS
- −120.0%
- Free cash flow
- +13.4%
- Total debt
- +57.4%
Quarter to June 2026, against a year earlier
Follow IBRX
Alert me
ImmunityBio, Inc. (IBRX) EV/FCF
As of 5 November 2026, ImmunityBio, Inc. (IBRX) trades at a EV/FCF of −32.5×. Over the past ten years it has ranged from −158× (July 2015) to 10.6× (March 2015); the current reading is higher than 8% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −8.2× | — |
| FY2024 | −6.5× | — |
| FY2023 | −9.0× | — |
| FY2022 | −5.7× | — |
| FY2021 | −9.2× | — |
| FY2020 | −29.9× | — |
| FY2019 | −8.7× | — |
| FY2018 | −0.5× | — |
| FY2017 | −2.9× | — |
| FY2016 | −6.4× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | −35.1× | — |
| Mar 2026 | −29.0× | — |
| Dec 2025 | −8.2× | — |
| Sep 2025 | −9.4× | — |
| 42 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| TWST Twist Bioscience Corporation compare | −77.9× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −64.5× |
| IBRX ImmunityBio, Inc. | −32.5× |
| SYRE Spyre Therapeutics, Inc. compare | −30.3× |
| CYTK Cytokinetics, Incorporated compare | −12.7× |
| KRYS Krystal Biotech, Inc. compare | 25.7× |
| PTGX Protagonist Therapeutics, Inc. compare | 62.4× |
| CAI Caris Life Sciences,�Inc. compare | 181× |
| TGTX TG Therapeutics, Inc. compare | 485× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on IBRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement